Johnson & Johnson's Q1 2024 results showcase strong growth with revenue reaching $21.4 billion, a 3.9% increase driven by 7.8% growth in the U.S. market. The company's net income stood at $5.4 billion, translating to diluted earnings per share (EPS) of $2.20, up significantly from a loss per share of $0.19 in the prior year. The results reflect robust performance in both the Innovative Medicine and MedTech segments, aided by ongoing product launches, acquisitions, and the positive market reception of key therapies. Management's outlook remains bullish, emphasizing confidence in achieving operational sales growth of 5.5% to 6.0% for the fiscal year, indicating a strategic positioning for future growth.